Tevogen Bio Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	19.95	23.43	4.44	8.43	1.66
Research & Development	10.94	30.14	4.4	5.29	2.96
Operating Expenses	30.89	53.56	8.84	13.72	4.62
Operating Income	-30.89	-53.56	-8.84	-13.72	-4.62
Interest Expense	-0.14	-0.18	-1.21	-0.93	-0.6
Interest & Investment Income	-	-	0	0	0
Other Non Operating Income (Expenses)	-0.01	-0.95	-	-	-
EBT Excluding Unusual Items	-31.04	-54.7	-10.05	-14.66	-5.22
Merger & Restructuring Charges	-	-7.5	-	-	-
Other Unusual Items	-	48.47	-50.43	-7.38	-10.38
Pretax Income	-31.04	-13.73	-60.48	-22.04	-15.6
Net Income	-31.04	-13.73	-60.48	-22.04	-15.6
Preferred Dividends & Other Adjustments	0.37	-3.45	-	-	-
Net Income to Common	-31.42	-10.27	-60.48	-22.04	-15.6
Shares Outstanding (Basic)	167	147	25	25	25
Shares Outstanding (Diluted)	167	147	25	25	25
Shares Change (YoY)	32.33%	492.57%	-1.98%	0.69%	-
EPS (Basic)	-0.19	-0.07	-2.44	-0.87	-0.62
EPS (Diluted)	-0.19	-0.07	-2.44	-0.87	-0.62
Free Cash Flow	-13.19	-12	-8.3	-9.13	-5.38
Free Cash Flow Per Share	-0.08	-0.08	-0.34	-0.36	-0.21
EBITDA	-30.72	-53.4	-8.68	-13.63	-4.61
D&A For EBITDA	0.17	0.16	0.16	0.09	0.01
EBIT	-30.89	-53.56	-8.84	-13.72	-4.62

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q